NCT02688075 (CanCARE) is a clinical trial of No Intervention in Diabetes Mellitus, Type 2, sponsored by Janssen Inc..

Who is sponsoring NCT02688075?

NCT02688075 is sponsored by Janssen Inc..

What drugs are being tested in NCT02688075?

Interventions in NCT02688075: No Intervention.

What condition does NCT02688075 study?

NCT02688075 studies Diabetes Mellitus, Type 2.

Is NCT02688075 still recruiting?

NCT02688075 is currently completed. Last updated 30 October 2017.

Last reviewed 2017-10-30 · How we verify

NCT02688075: CanCARE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

An Observational Study to Assess the Canagliflozin Treatment in Type 2 Diabetes Mellitus in a Usual Clinical Practice in Canada

Completed Last updated 30 October 2017

What this trial tests

trial testing No Intervention in Diabetes Mellitus, Type 2 in 538 participants. Completed in 17 August 2017.

Timeline

13 November 2015

Primary endpoint
17 August 2017

17 August 2017

Quick facts

Lead sponsor	Janssen Inc.
Status	Completed
Study type	OBSERVATIONAL
Enrollment	538
Start date	13 November 2015
Primary completion	17 August 2017
Estimated completion	17 August 2017
Sites	23 locations across Canada

Drugs / interventions tested

No Intervention

Conditions studied

Diabetes Mellitus, Type 2 — all drugs for Diabetes Mellitus, Type 2 →

Sponsor

Janssen Inc. — full company profile →

Who can join

18 and older, any sex, with Diabetes Mellitus, Type 2. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate canagliflozin use in the treatment of type 2 diabetes mellitus (T2DM) and generate evidence of its effectiveness, safety and patient-reported outcome (PRO) in a usual clinical practice in Canada.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

53 <sup>rd</sup> EASD Annual Meeting of the European Association for the Study of Diabetes : Lisbon, Portugal, 11 - 15 September 2017.
· 2017 · cited 17× · PMID 28795195 · DOI 10.1007/s00125-017-4350-z
CANadian CAnagliflozin REgistry: Effectiveness and safety of canagliflozin in the treatment of type 2 diabetes mellitus in Canadian clinical practice.
Woo V, Bell A, Clement M, Noronha L, et al · · 2019 · cited 7× · PMID 30393961 · DOI 10.1111/dom.13573

Verify or expand the search:

Other trials of No Intervention

Trials testing the same drug.

NCT07353099 — A Study in Children and, Adults With Congenital Thrombotic Thrombocytopenic Purpura (cTTP) Treated With Adzynma · not yet recruiting
NCT07429942 — A Study to Learn More About the Treatment of People With Congenital Thrombotic Thrombocytopenic Purpura (cTTP) Who Recei · not yet recruiting
NCT07521917 — Child Abuse and Neglect Awareness Training in Nursing Students · NA · not yet recruiting
NCT07319832 — A Study of Teduglutide in Chinese Children and Teenagers With Short Bowel Syndrome · recruiting
NCT07425574 — A Study to Learn How Stargardt-type Eye Conditions Progress in Children and Adults · recruiting

Other recruiting trials for Diabetes Mellitus, Type 2

Currently open trials in the same condition.

NCT07415954 — A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 · Phase 2 · recruiting
NCT07532863 — A Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) Part · recruiting
NCT07336329 — Continuous Glucose Monitoring in Non-Insulin Treated Type 2 Diabetes: Continuous vs. Periodic Use · NA · recruiting
NCT07242469 — A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006) · Phase 1 · recruiting
NCT07444203 — Transformative Research in Diabetic Nephropathy 2.0 · recruiting

Other Janssen Inc. trials

Trials by the same sponsor.

NCT03729349 — Golimumab for Adherence in Rheumatoid Arthritis · completed
NCT03501173 — A Study of Participants With Advanced Prostate Cancer in Canada · completed
NCT02364531 — A Canadian Observational Study in Metastatic Cancer of the Prostate: A Study of ZYTIGA Use in the Community Urology Sett · completed
NCT01483599 — A Study to Evaluate CNTO 1959 in the Treatment of Patients With Moderate to Severe Plaque-type Psoriasis · Phase 2 · completed
NCT00741793 — Biologic Treatment Registry Across Canada · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02688075 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Janssen Inc.
Last refreshed: 30 October 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02688075.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing